Key result
Anti-IL-5 and IL-4/13 antibodies linked to improved functional status in ~77% of eosinophilic myocarditis patients.
Why the study?
Monoclonal antibodies targeting IL-5/5R or IL-4/13 control systemic eosinophilic manifestations, but their effectiveness and safety in eosinophilic myocarditis remained unexplored.
Do monoclonal antibodies targeting IL-5/5R and IL-4/13 pathways improve clinical and echocardiographic outcomes in patients with eosinophilic myocarditis?
Population
13 patients with eosinophilic myocarditis at a single tertiary care center
Comparison
Anti-IL-5/5R or anti-IL-4/13 therapy
Design
Single-center retrospective cohort study
Follow-up
54±34 months
Authors
Loading...
May offer steroid-sparing option in eosinophilic myocarditis; hypothesis-generating from Level 3 data and leaves open need for RCTs.
Do monoclonal antibodies targeting IL-5/5R and IL-4/13 pathways improve clinical and echocardiographic outcomes in patients with eosinophilic myocarditis?
Monoclonal antibodies targeting IL-5/5R and IL-4/13 pathways appear safe and effective for treating eosinophilic myocarditis, improving LVEF and allowing for corticosteroid discontinuation.
Menghi et al. (2025) studied this question. Monoclonal antibodies targeting IL-5 and IL-4/13 improved functional status in 77% of eosinophilic myocarditis patients, with LVEF rising from 46% to 53% at follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: